Genetic modifiers of sickle cell anemia in the baby hug cohort: Influence on laboratory and clinical phenotypes

American Journal of Hematology

Volumn 88, Issue 7, 2013, Pages 571-576

  Sheehan, Vivien A ^a   Luo, Zhaoyu ^b   Flanagan, Jonathan M ^a   Howard, Thad A ^a   Thompson, Bruce W ^b   Wang, Winfred C ^c   Kutlar, Abdullah ^d   Ware, Russell E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Clinical Trials & Surveys Corp   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d Georgia Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; GENOMIC DNA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HYDROXYUREA;

ALPHA THALASSEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HAPLOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PAIN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RETICULOCYTE COUNT; SICKLE CELL ANEMIA;

ALPHA-THALASSEMIA; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BETA-GLOBINS; BILIRUBIN; CARRIER PROTEINS; CHILD, PRESCHOOL; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; FEMALE; FETAL HEMOGLOBIN; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; HYDROXYUREA; INFANT; MALE; NUCLEAR PROTEINS; ONCOGENE PROTEINS V-MYB; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 84879327608     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23457     Document Type: Article

References (45)

1. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 1995;86:776-783.
2. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000;342:83-89.
3. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: Baseline data from the BABY HUG trial. J Pediatr 2010;156:66-70 e61.
4. Chui DH, Dover GJ. Sickle cell disease: No longer a single gene disorder. Curr Opin Pediatr 2001;13:22-27.
5. Ballas SK. Effect of alpha-globin genotype on the pathophysiology of sickle cell disease. Pediatr Pathol Mol Med 2001;20:107-121.
6. Billett HH, Nagel RL, Fabry ME. Paradoxical increase of painful crises in sickle cell patients with alpha-thalassemia. Blood 1995;86:4382.
7. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res 1993:136-143.
8. Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. N Engl J Med 1985;312:880-884.
9. Powars DR. Beta s-gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. Hematol Oncol Clin North Am 1991;5:475-493.
10. Powars DR, Meiselman HJ, Fisher TC, et al. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity. Am J Pediatr Hematol Oncol 1994;16:55-61.
11. Rieder RF, Safaya S, Gillette P, et al. Effect of beta-globin gene cluster haplotype on the hematological and clinical features of sickle cell anemia. Am J Hematol 1991;36:184-189.
12. Gilman JG, Huisman TH. A mutation associated with elevated G gamma chain in sickle cell anemia and hereditary persistence of fetal hemoglobin. Prog Clin Biol Res 1985;191:141-149.
13. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 2008;105:1620-1625.
14. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839-1842.
15. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci USA 2007;104:11346-11351.
16. Passon RG, Howard TA, Zimmerman SA, et al. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 2001;23:448-451.
17. Vasavda N, Menzel S, Kondaveeti S, et al. The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol 2007;138:263-270.
18. Heeney MM, Howard TA, Zimmerman SA, et al. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med 2003;141:279-282.
19. Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood 2008;112:4314-4317.
20. Flanagan JM, Frohlich DM, Howard TA, et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 2011;117:6681-6684.
21. Miller ST, Milton J, Steinberg MH. G6PD deficiency and stroke in the CSSCD. Am J Hematol 2010;86:331.
22. Nouraie M, Reading NS, Campbell A, et al. Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. Br J Haematol 2010;150:218-225.
23. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-1672.
24. Pavlakis SG, Rees RC, Huang X, et al. Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: Baseline data from the BABY HUG trial. Pediatr Blood Cancer 2010;54:256-259.
25. McCarville MB, Luo Z, Huang X, et al. Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: Baseline data from the BABY HUG trial. AJR Am J Roentgenol 2011;196:1399-1404.
26. Tan AS, Quah TC, Low PS, et al. A rapid and reliable 7-deletion multiplex polymerase chain reaction assay for alpha-thalassemia. Blood 2001;98:250-251.
27. Sutton M, Bouhassira EE, Nagel RL. Polymerase chain reaction amplification applied to the determination of beta-like globin gene cluster haplotypes. Am J Hematol 1989;32:66-69.
28. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989.
29. Chaar V, Keclard L, Etienne-Julan M, et al. UGT1A1 polymorphism outweighs the modest effect of deletional (-3.7 kb) alpha-thalassemia on cholelithogenesis in sickle cell anemia. Am J Hematol 2006;81:377-379.
30. Serjeant G, Serjeant B, Stephens A, et al. Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Br J Haematol 1996;92:143-149.
31. Serjeant GR. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol 1995;2:103-108.
32. Morelli A, Benatti U, Gaetani GF, et al. Biochemical mechanisms of glucose-6-phosphate dehydrogenase deficiency. Proc Natl Acad Sci USA 1978;75:1979-1983.
33. Steinberg MH, West MS, Gallagher D, et al. Effects of glucose-6-phosphate dehydrogenase deficiency upon sickle cell anemia. Blood 1988;71:748-752.
34. Rees DC, Lambert C, Cooper E, et al. Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia. Blood 2009;114:742-743; author reply 743-744.
35. Haverfield EV, McKenzie CA, Forrester T, et al. UGT1A1 variation and gallstone formation in sickle cell disease. Blood 2005;105:968-972.
36. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011;118:4985-4991.
37. Gilman JG, Huisman TH. DNA sequence variation associated with elevated fetal G gamma globin production. Blood 1985;66:783-787.
38. Labie D, Pagnier J, Lapoumeroulie C, et al. Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci USA 1985;82:2111-2114.
39. Vasavda N, Woodley C, Allman M, et al. Effects of co-existing alpha-thalassaemia in sickle cell disease on hydroxycarbamide therapy and circulating nucleic acids. Br J Haematol 2012;157:249-252.
40. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605-610.
41. Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol 1994;45:279-282.
42. Belisario AR, Rodrigues CV, Martins ML, et al. Coinheritance of alpha-thalassemia decreases the risk of cerebrovascular disease in a cohort of children with sickle cell anemia. Hemoglobin 2010;34:516-529.
43. Hsu LL, Miller ST, Wright E, et al. Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 2003;25:622-628.
44. Schroeder WA, Powars DR, Kay LM, et al. Beta-cluster haplotypes, alpha-gene status, and hematological data from SS, SC, and S-beta-thalassemia patients in southern California. Hemoglobin 1989;13:325-353.
45. Belisario AR, Martins ML, Brito AM, et al. beta-globin gene cluster haplotypes in a cohort of 221 children with sickle cell anemia or Sbeta-thalassemia and their association with clinical and hematological features. Acta Haematol 2010;124:162-170.